Venetoclax-based combinations for the treatment of newly diagnosed acute myeloid leukemia

Tamer A. Othman, Tali Azenkot, Benjamin N. Moskoff, Matthew E. Tenold, Brian A. Jonas

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Elderly and/or unfit patients with acute myeloid leukemia have historically been challenging to manage as they were ineligible for what was considered standard of care treatment with induction chemotherapy. The emergence of venetoclax with hypomethylating agents or low-dose cytarabine has substantially improved outcomes in the frontline setting with manageable toxicity. However, this regimen can be challenging to deliver given its differences from standard intensive chemotherapy. In this review, we summarize the landmark trials that established venetoclax-based combinations as a new standard of care for patients with acute myeloid leukemia not suitable for intense chemotherapy, provide practical clinical pearls for managing patients on these therapies, and offer a brief overview of modifications to these regimens under development to improve their efficacy and/or applicability. Lay abstract Older and/or unfit patients with acute myeloid leukemia (AML) have historically had bad outcomes with standard therapies and an overall dismal prognosis. The advent of venetoclax (VEN)-based regimens has led to significantly improved responses for patients with untreated AML with an acceptable safety profile. However, delivering these therapies are associated with their own unique challenges. In this review, we summarize the key trials that demonstrated the success of VEN-based combinations in this particular AML population, provide practical considerations for managing patients on these therapies, and discuss ongoing studies to further improve VEN-based therapy.

Original languageEnglish (US)
Pages (from-to)2989-3005
Number of pages17
JournalFuture Oncology
Volume17
Issue number23
DOIs
StatePublished - Aug 2021

Keywords

  • acute myeloid leukemia
  • AML
  • azacitidine
  • BCL-2
  • decitabine
  • HMA
  • hypomethylating agent
  • LDAC
  • measurable residual disease
  • venetoclax

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Venetoclax-based combinations for the treatment of newly diagnosed acute myeloid leukemia'. Together they form a unique fingerprint.

Cite this